Group 1 - The company held its second extraordinary shareholders' meeting on September 5, 2025, where a new board of directors was elected, consisting of 3 non-independent directors, 2 independent directors, and 1 employee representative director [1][2] - The first meeting of the newly elected board was convened on the same day, with all 6 directors present, and was chaired by Mr. Cheng Xianfeng [1][2] - Mr. Cheng Xianfeng was elected as the chairman of the ninth board of directors, with a term of three years from the date of the meeting [1][2] Group 2 - The board approved the appointment of senior management, including the reappointment of Mr. Cheng Xianfeng as president and the appointment of Mr. Feng Dexi as senior vice president and board secretary [2][3] - Other appointments included Mr. Wang Feng, Ms. Geng Yuhong, and Ms. Qian Liping as executive vice presidents, and Mr. Zhang Dawai as vice president and CFO, all with a term of three years [2][3] Group 3 - The board expressed gratitude to the outgoing directors, supervisors, and senior management for their contributions during their tenure [3][4] - The independent directors Cheng Genhong and Liu Hongquan, along with other members of the eighth board, completed their terms and will not hold any other positions in the company [3][4] Group 4 - The company’s audit committee will assume the responsibilities of the supervisory board as per legal requirements, following the completion of the eighth board's term [3][4] - The company has ensured compliance with relevant laws and regulations regarding the appointment and responsibilities of its directors and management [3][4]

Meeting Overview - The shareholder meeting of Yifan Pharmaceutical Co., Ltd. was held on September 5, 2025, with both on-site and online voting options available [1][2] - A total of 305 shareholders and representatives participated, representing 523,447,918 shares, which is 43.0329% of the total voting shares [1] Voting Participation - Among the participants, 298 were small investors and authorized representatives, with 24,242,411 shares represented, accounting for 1.9930% of the total voting shares [2] Proposal Voting Results - The following proposals were approved during the meeting: Amendment of Company Articles - The proposal to amend the Articles of Association received 99.9397% approval, with 523,132,518 votes in favor [2] Amendment of Shareholder Meeting Rules - The proposal to amend the Rules of Procedure for Shareholder Meetings was approved with 98.2548% support, totaling 514,312,460 votes [3] Amendment of Board Meeting Rules - The proposal to amend the Rules of Procedure for Board Meetings was approved with 98.2528% support, totaling 514,302,460 votes [4] Amendment of Independent Director Work System - The proposal to amend the Independent Director Work System received 98.2537% approval, with 514,307,160 votes in favor [4] Amendment of Fund Management Measures - The proposal to amend the Fund Management Measures was approved with 98.2552% support, totaling 514,314,660 votes [5] Amendment of Related Party Transaction Decision-Making System - The proposal to amend the Related Party Transaction Decision-Making System received 98.2542% approval, with 514,309,760 votes in favor [6] Amendment of Investment Management System - The proposal to amend the Investment Management System was approved with 98.2539% support, totaling 514,307,960 votes [6] Amendment of Accountant Selection System - The proposal to amend the Accountant Selection System received 98.2544% approval, with 514,310,660 votes in favor [7] Adjustment of Independent Director Allowances - The proposal to adjust the allowances for independent directors was approved with 99.9303% support, totaling 523,083,218 votes [8] Election of Non-Independent Directors - The election of non-independent directors was approved with 97.2691% support, totaling 509,153,070 votes [8] Election of Independent Directors - The election of independent directors received 99.4032% approval, with 520,324,012 votes in favor [9] Legal Opinion - The meeting was witnessed by lawyers from Anhui Tianhe Law Firm, confirming that the meeting's procedures and resolutions complied with relevant laws and regulations [9]

Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms that the procedures for the second extraordinary general meeting of Yifan Pharmaceutical Co., Ltd. in 2025 comply with relevant laws and regulations, and the voting results are valid and legal [1][16]. Group 1: Meeting Procedures - The board of directors approved the proposal to convene the second extraordinary general meeting on August 13, 2025 [1]. - The notice for the meeting was published on August 15, 2025, in compliance with the 15-day prior notice requirement [2]. - The meeting will include both on-site and online voting, with specific time slots for each [2]. - The on-site meeting is scheduled for September 5, 2025, at a designated location in Hefei, Anhui Province [2]. Group 2: Attendance and Voting - A total of 305 shareholders and representatives attended the meeting, representing 523,447,918 shares, which is 43.0329% of the total voting shares [3]. - Of the attendees, 8 were present on-site, representing 499,217,507 shares (41.0409%), while 297 participated via online voting, representing 24,230,411 shares (1.9920%) [3]. - The qualifications of all attendees, including shareholders, representatives, and company executives, were verified and deemed compliant with legal requirements [3]. Group 3: Voting Results - The meeting reviewed and voted on several proposals, all of which were consistent with the previously announced agenda [4]. - The voting process combined on-site and online methods, with results announced immediately after the voting period [4]. - The first proposal received 523,132,518 votes in favor, accounting for 99.9397% of the valid votes cast [4]. - The voting results for small investors showed 23,927,011 votes in favor, representing 98.6990% of their valid votes [5]. - Other proposals, including amendments to various internal regulations, also received overwhelming support, with approval rates generally above 98% [6][10][12].

Core Viewpoint - Yifan Pharmaceutical Co., Ltd. has elected Mr. Zhou Benyu as the employee representative director for the ninth board of directors, ensuring the continuity of the board's operations following the expiration of the eighth board's term [1][2][3]. Group 1: Board Composition - The board of directors consists of six members, including one employee representative director elected by the employee representative assembly [1]. - Mr. Zhou Benyu will join five non-employee representative directors elected by the shareholders to form the ninth board, with a term starting from the approval date of the employee representative assembly [1]. Group 2: Mr. Zhou Benyu's Profile - Mr. Zhou Benyu, born in September 1973, is a senior accountant and economist with over 20 years of experience in the pharmaceutical industry [4]. - He has served as a director of the company since October 2014 and has been the employee representative director since the recent election [4]. - Mr. Zhou holds 391,900 shares of the company and has no conflicts of interest with other major shareholders or board members [4].

Group 1 - Yifan Pharmaceutical (SZ 002019) held its first extraordinary board meeting of the ninth session on September 5, 2025, to discuss the election of the chairman and other related matters [1] - For the first half of 2025, Yifan Pharmaceutical's revenue composition was as follows: pharmaceuticals accounted for 85.53%, pharmaceutical raw materials and intermediates accounted for 11.47%, and high polymer materials accounted for 3.0% [1] - As of the report date, Yifan Pharmaceutical's market capitalization was 19 billion yuan [1] Group 2 - Haidilao is diversifying its business with initiatives such as opening a bakery by West Lake and entering the high-end hotel sector, but the survival rate of its sub-brands is less than 50% [1]

上述职工代表董事符合《中华人民共和国公司法》等法律法规规定的任职条件。 董事会中兼任公司高级管理人员及由职工代表担任的董事人数总计不超过公司董事 总数的二分之一。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-057 亿帆医药股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）第八届董事会任期已经届满。为 保证公司董事会的正常运作，依据《中华人民共和国公司法》等相关法律、法规及 规范性文件和《公司章程》的相关规定，公司董事会由6名董事组成，其中一名为职 工代表董事，由公司职工代表大会选举产生。 公司于2025年9月5日在公司会议室召开第三届三次职工代表大会，经与会职工 代表认真审议，以无记名投票表决的方式，一致同意选举周本余先生为公司第九届 董事会职工代表董事（简历附后）。 周本余先生将与公司股东会选举产生的5名非职工代表董事共同组成公司第九 届董事会，任期自本次职工代表大会审议通过之日起至第九届董事会任期届满之日 止。 特此公告。 亿帆医药股份有限公司董事会 20 ...

法律意见书 安徽天禾律师事务所 关于亿帆医药股份有限公司 之法律意见书 致：亿帆医药股份有限公司 根据《中华人民共和国公司法》（下称《公司法》）、《中华人民共和国证券法》 （下称《证券法》）、中国证券监督管理委员会（下称"中国证监会"）《上市公司 股东会规则》（下称《股东会规则》）以及《亿帆医药股份有限公司公司章程》（下 称《公司章程》）等有关规定，安徽天禾律师事务所接受亿帆医药股份有限公司（下 称"亿帆医药"或"公司"）委托，指派凌斌、洪嘉玉律师（下称"天禾律师"）出 席公司 2025 年第二次临时股东会（下称"本次股东会"），对本次股东会相关事项 进行见证，并出具法律意见。 本法律意见书是天禾律师根据对有关本次股东会事实的了解及对我国现行法律、 法规和规范性文件的理解而做出的。 天禾律师同意将本法律意见书作为本次股东会的必备文件予以公告并依法对所出 具的法律意见书承担责任。 天禾律师根据有关法律、法规的要求，按照律师行业公认的业务标准、道德规范 和勤勉尽责的精神，对本次股东会的召集和召开程序、出席会议人员的资格、表决程 序及其他相关法律问题发表法律意见如下： 2025 年第二次临时股东会 一、本次股东会的 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-056 亿帆医药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东会无否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间 现场会议召开的时间：2025 年 9 月 5 日下午 1:30 起 网络投票的时间：2025 年 9 月 5 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 5 日上午 9:15 至 9:25，9:30 至 11:30，下午 13:00 至 15:00； 通过深圳证券交易所互联网投票系统进行网络投票，开始时间为 2025 年 9 月 5 日上午 9:15 至下午 15:00。 2、现场会议召开地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口， 合肥亿帆生物制药有限公司会议室 3、召集人：公司董事会 4、会议方式：本次会议采取现场投票和网络投票相结合的方式 3、参加投票的中小股东情况： ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-058 亿帆医药股份有限公司 第九届董事会第一次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）于2025年9月5日召开了2025年第 二次临时股东会，由股东会以累积投票方式选举的3名非独立董事和2名独立董事， 以及由职工代表大会民主选举方式产生的1名职工代表董事共同组成公司第九届 董事会，完成了董事会换届选举工作。 为保证董事会工作的衔接性和连贯性，公司第九届董事会第一次（临时）会 议通知于当天以口头的方式发出，以现场的方式在子公司一楼会议室召开。会议 应出席董事6名，实际出席董事6名，经全体董事共同推举，本次董事会由董事程 先锋先生主持。本次会议的召集和召开符合《公司法》和《公司章程》等有关规 定。 二、董事会会议审议情况 经全体董事认真审议，会议以投票表决的方式形成以下决议： （一）会议以6票同意、0票反对、0票弃权的结果，审议通过了《关于选举 公司第九届董事会董事长暨代表公司执行公司事务的董事的议案》 董 ...

Group 1 - The company Yifan Pharmaceutical reported that as of August 29, 2025, the number of shareholders is 42,857 [2]